Patent · US Active

Antibodies binding to VISTA at acidic pH

US12195535B2 · kind B2 · utility

0Cited by

6References

37Claims

0Family size

Assignees

Five Prime Therapeutics, Inc. · US
Bristol-Myers Squibb Company · US

Inventors

Robert J. Johnston · San Mateo, US
Arvind Rajpal · San Francisco, US
Paul O. Sheppard · Granite Falls, US
Luis Borges · Seattle, US
Andrew Rankin · Redwood City, US
Keith Sadoon Bahjat · Portland, US
Alan J. Korman · Piedmont, US
Andy X. Deng · Princeton, US
Lin Hui Su · Somerville, US
Ginger Rakestraw · Cambridge, US

Key dates

Filing date	Feb 1, 2023
Grant date	Jan 14, 2025
Priority date	—
Expiry date	Feb 1, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.